Press Resease

Ophthalmic Drugs Market by Drug Class (Anti-inflammatory Drugs [Non Steroidal Anti-Inflammatory Drugs and Steroids], Anti-Infective Drugs [Anti-Fungal Drugs, Anti-Bacterial Drugs, Anti-Viral Drugs, and Others], Anti-Glaucoma Drugs [Alpha Agonist, Beta Blockers, Prostaglandin Analogs, Combined Medication, and Others], Anti-Allergic Drugs, and Others), by Type (Prescription Drugs and Over-the-Counter Drugs), by Disease Indication (Dry Eye, Allergies, Glaucoma, Retinal Disorders, Inflammation/ Infection, Uveitis, and Others), and by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Sales, and Others): Global Industry Perspective, Comprehensive Analysis and Forecast, 2017 - 2024

Published Date: 20-Sep-2018 Category: Pharmaceutical Report Format : PDF Pages: 110 Report Code: ZMR-3372 Status : Published

Global ophthalmic drugs market expected to generate revenue of around USD 34.52 billion by end of 2024, growing at a CAGR of around 4.70% between 2018 and 2024. Ophthalmic drugs are used in the treatment of cataract, retinopathy, glaucoma, diabetic, and other disorders.

Description

The report covers forecast and analysis for the ophthalmic drugs market on a global and regional level. The study provides historical data from 2015 to 2017 along with a forecast from 2018 to 2024 based on revenue (USD Billion). The study includes drivers and restraints for the ophthalmic drugs market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the ophthalmic drugs market on a global level.

In order to give the users of this report a comprehensive view of the ophthalmic drugs market, we have included competitive landscape and analysis of Porter’s Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein drug class, type, disease indication, distribution channel, and regional segments are benchmarked based on their market size, growth rate, and general attractiveness.

Global Ophthalmic Drugs Market

The report provides company market share analysis in order to give a broader overview of the key players in the market. In addition, the report also covers key strategic developments of the market including acquisitions & mergers, new product launches, agreements, partnerships, collaborations & joint ventures, research & development, and regional expansion of major participants involved in the market on the global and regional basis. 

The study provides a decisive view of the ophthalmic drugs market by segmenting the market based on drug class, type, disease indication, distribution channel, and regions. All the segments have been analyzed based on present and future trends and the market is estimated from 2018 to 2024. The regional segmentation includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa with its further divided into major countries.

Some of the leading players in ophthalmic drugs market include Allergan Plc, Regeneron Pharmaceuticals, Inc., Pfizer, Inc., Novartis AG, Bayer AG, F.Hoffmann-La Roche Ltd., Santen Pharmaceutical Co., Ltd., Kyowa Hakka Kirin Co., Ltd., Valent Pharmaceuticals International, Inc., Johnson and Johnson Vision Care, Inc. and Shire Plc.

This report segments the global ophthalmic drugs market as follows:

Global Ophthalmic Drugs Market: Drug Class Segment Analysis

  • Anti-Inflammatory Drugs
    • Non-Steroidal Anti-Inflammatory Drugs
    • Steroids 
  • Anti-Infective Drugs
    • Anti-Fungal Drugs
    • Anti-Bacterial Drugs
    • Anti-Viral Drugs
    • Others
  • Anti-Glaucoma Drugs
    • Alpha Agonist
    • Beta Blockers
    • Prostaglandin Analogs
    • Combined Medication
    • Others 
  • Anti-Allergic Drugs
  • Others

Global Ophthalmic Drugs Market: Type Segment Analysis

  • Prescription Drugs
  • Over-the-Counter Drugs

Global Ophthalmic Drugs Market: Disease Indication Segment Analysis

  • Dry Eye
  • Allergies
  • Glaucoma
  • Retinal Disorders
  • Inflammation/ Infection
  • Uveitis
  • Others

Global Ophthalmic Drugs Market: Distribution Channel Segment Analysis

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Sales
  • Others

Global Ophthalmic Drugs Market: Regional Segment Analysis

  • North America
    • The U.S.
  • Europe
    • UK
    • France
    • Germany
  • Asia Pacific
    • China
    • Japan
    • India
  • Latin America
    • Brazil
  • The Middle East and Africa

Table Of Content

  • Chapter 1. Introduction
    • 1.1. Report description and scope
    • 1.2. Research scope
    • 1.3. Research methodology
      • 1.3.1. Market research process
      • 1.3.2. Market research methodology
  •  
  • Chapter 2. Executive Summary
    • 2.1. Global ophthalmic drugs market, 2017 - 2024 (USD Billion)
    • 2.2. Global ophthalmic drugs market : snapshot
  •  
  • Chapter 3. Ophthalmic Drugs Market - Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Global ophthalmic drugs market drivers: impact analysis
      • 3.2.2. Increase in focus of key players to develop combination therapies for the treatment of ophthalmic disorders
      • 3.2.3. Presence of strong emerging pipeline drugs
      • 3.2.4. Increased funding from both public and private research organizations
    • 3.3. Market Restraints
      • 3.3.1. Global ophthalmic drugs market restraints: impact analysis
      • 3.3.2. Longer timelines required for the drug development
      • 3.3.3. Loss of patent protection for blockbuster drugs
    • 3.4. Opportunities
      • 3.4.1. Increase in investment by market players in the emerging economies
    • 3.5. Porter's five forces analysis
      • 3.5.1. Bargaining power of suppliers
      • 3.5.2. Bargaining power of buyers
      • 3.5.3. Threat from new entrants
      • 3.5.4. Threat from new substitutes
      • 3.5.5. Degree of competition
    • 3.6. Market Attractiveness Analysis
      • 3.6.1. Market attractiveness analysis, by drug class segment
      • 3.6.2. Market attractiveness analysis, by type segment
      • 3.6.3. Market attractiveness analysis, by disease indication segment
      • 3.6.4. Market attractiveness analysis, by distribution channel segment
      • 3.6.5. Market attractiveness analysis, by regional segment
  •  
  • Chapter 4. Global Ophthalmic Drugs Market - Competitive Landscape
    • 4.1. Company market share analysis
      • 4.1.1. Global ophthalmic drugs market : company market share, 2017
    • 4.2. Strategic development
      • 4.2.1. Acquisitions & mergers
      • 4.2.2. New therapy launch
      • 4.2.3. Agreements, partnerships, collaborations and joint ventures
      • 4.2.4. Research and development and regional expansion
    • 4.3. Price trend analysis
  •  
  • Chapter 5. Global Ophthalmic Drugs Market - Drug Class Segment Analysis
    • 5.1. Global ophthalmic drugs market : drug class overview
      • 5.1.1. Global ophthalmic drugs market revenue share, by drug class, 2017 and 2024
    • 5.2. Anti-Inflammatory Drugs
      • 5.2.1. Global ophthalmic drugs market for anti-inflammatory drugs, 2017 - 2024 (USD Billion)
        • 5.2.1.1. Non-Steroidal Anti-Inflammatory Drugs
          • 5.2.1.1.1. Global anti-inflammatory drugs market, by non-steroidal anti-inflammatory drugs, 2017 - 2024 (USD Billion)
        • 5.2.1.2. Steroids
          • 5.2.1.2.1. Global anti-inflammatory drugs market, by steroids, 2017 - 2024 (USD Billion)
    • 5.3. Anti-Infective Drugs
      • 5.3.1. Global ophthalmic drugs market for anti-infective drugs, 2017 - 2024 (USD Billion)
        • 5.3.1.1. Anti-Fungal Drugs
          • 5.3.1.1.1. Global anti-infective drugs market, by anti-fungal drugs, 2017 - 2024 (USD Billion)
        • 5.3.1.2. Anti-Bacterial Drugs
          • 5.3.1.2.1. Global anti-infective drugs market, by anti-bacterial drugs, 2017 - 2024 (USD Billion)
        • 5.3.1.3. Anti-viral Drugs
          • 5.3.1.3.1. Global anti-infective drugs market, by anti-viral drugs, 2017 - 2024 (USD Billion)
        • 5.3.1.4. Others
        • 5.3.1.4.1. Global anti-infective drugs market, by others, 2017 - 2024 (USD Billion)
    • 5.4. Anti-Glaucoma Drugs
      • 5.4.1. Global ophthalmic drugs market for anti-glaucoma drugs, 2017 - 2024 (USD Billion)
        • 5.4.1.1. Alpha Agonist
          • 5.4.1.1.1. Global anti-glaucoma drugs market, by alpha agonist, 2017 - 2024 (USD Billion)
        • 5.4.1.2. Beta Blockers
          • 5.4.1.2.1. Global anti-glaucoma drugs market, by beta blockers, 2017 - 2024 (USD Billion)
        • 5.4.1.3. Prostaglandin Analogs
          • 5.4.1.3.1. Global anti-glaucoma drugs market, by prostaglandin analogs, 2017 - 2024 (USD Billion)
        • 5.4.1.4. Combined Medication
          • 5.4.1.4.1. Global anti-glaucoma drugs market, by combined medication, 2017 - 2024 (USD Billion)
        • 5.4.1.5. Others
          • 5.4.1.5.1. Global anti-glaucoma drugs market, by others, 2017 - 2024 (USD Billion)
    • 5.5. Anti-Allergic Drugs
      • 5.5.1. Global ophthalmic drugs market for anti-allergic drugs, 2017 - 2024 (USD Billion)
    • 5.6. Others
      • 5.6.1. Global ophthalmic drugs market for others, 2017 - 2024 (USD Billion)
  •  
  • Chapter 6. Global Ophthalmic Drugs Market -Type Segment Analysis
    • 6.1. Global ophthalmic drugs market : Type overview
      • 6.1.1. Global ophthalmic drugs market revenue share, by type, 2017 and 2024
    • 6.2. Prescription Drugs
      • 6.2.1. Global ophthalmic drugs market for prescription drugs, 2017 - 2024 (USD Billion)
    • 6.3. Over-the-Counter Drugs
      • 6.3.1. Global ophthalmic drugs market for over-the-counter drugs, 2017 - 2024 (USD Billion)
  •  
  • Chapter 7. Global Ophthalmic Drugs Market - Disease Indication Segment Analysis
    • 7.1. Global ophthalmic drugs market : distribution channel overview
      • 7.1.1. Global ophthalmic drugs market revenue share, by distribution channel, 2017 and 2024
    • 7.2. Dry Eye
      • 7.2.1. Global ophthalmic drugs market for dry eye, 2017 - 2024 (USD Billion)
    • 7.3. Allergies
      • 7.3.1. Global ophthalmic drugs market for allergies, 2017 - 2024 (USD Billion)
    • 7.4. Glaucoma
      • 7.4.1. Global ophthalmic drugs market for glaucoma, 2017 - 2024 (USD Billion)
    • 7.5. Retinal Disorders
      • 7.5.1. Global ophthalmic drugs market for retinal disorders, 2017 - 2024 (USD Billion)
    • 7.6. Inflammation/ Infection
      • 7.6.1. Global ophthalmic drugs market for inflammation/ infection, 2017 - 2024 (USD Billion)
    • 7.7. Uveitis
      • 7.7.1. Global ophthalmic drugs market for uveitis, 2017 - 2024 (USD Billion)
    • 7.8. Others
      • 7.8.1. Global ophthalmic drugs market for others, 2017 - 2024 (USD Billion)
  •  
  • Chapter 8. Global Ophthalmic Drugs Market - Distribution Channel Segment Analysis
    • 8.1. Global ophthalmic drugs market : distribution channel overview
      • 8.1.1. Global ophthalmic drugs market revenue share, by distribution channel, 2017 and 2024
    • 8.2. Hospital Pharmacies
      • 8.2.1. Global ophthalmic drugs market for hospital pharmacies, 2017 - 2024 (USD Billion)
    • 8.3. Retail Pharmacies
      • 8.3.1. Global ophthalmic drugs market for retail pharmacies, 2017 - 2024 (USD Billion)
    • 8.4. Online Sales
      • 8.4.1. Global ophthalmic drugs market for online sales, 2017 - 2024 (USD Billion)
    • 8.5. Others
      • 8.5.1. Global ophthalmic drugs market for others, 2017 - 2024 (USD Billion)
  •  
  • Chapter 9. Global Ophthalmic Drugs Market - Regional Segment Analysis
    • 9.1. Global ophthalmic drugs market : regional overview
      • 9.1.1. Global ophthalmic drugs market revenue share, by region, 2017 and 2024
    • 9.2. North America
      • 9.2.1. North America ophthalmic drugs market revenue, by drug class, 2017 - 2024 (USD Billion)
      • 9.2.2. North America ophthalmic drugs market revenue, by type, 2017 - 2024 (USD Billion)
      • 9.2.3. North America ophthalmic drugs market revenue, by disease indication, 2017 - 2024 (USD Billion)
      • 9.2.4. North America ophthalmic drugs market revenue, by distribution channel, 2017 - 2024 (USD Billion)
      • 9.2.5. The U.S.
        • 9.2.5.1. The U.S. ophthalmic drugs market revenue, by drug class, 2017 - 2024 (USD Billion)
        • 9.2.5.2. The U.S. ophthalmic drugs market revenue, by type, 2017 - 2024 (USD Billion)
        • 9.2.5.3. The U.S. ophthalmic drugs market revenue, by disease indication, 2017 - 2024 (USD Billion)
        • 9.2.5.4. The U.S. ophthalmic drugs market revenue, by distribution channel, 2017 - 2024 (USD Billion)
      • 9.2.6. Canada
        • 9.2.6.1. Canada ophthalmic drugs market revenue, by drug class, 2017 - 2024 (USD Billion)
        • 9.2.6.2. Canada ophthalmic drugs market revenue, by type, 2017 - 2024 (USD Billion)
        • 9.2.6.3. Canada ophthalmic drugs market revenue, by disease indication, 2017 - 2024 (USD Billion)
        • 9.2.6.4. Canada ophthalmic drugs market revenue, by distribution channel, 2017 - 2024 (USD Billion)
    • 9.3. Europe
      • 9.3.1. Europe ophthalmic drugs market revenue, by drug class, 2017 - 2024 (USD Billion)
      • 9.3.2. Europe ophthalmic drugs market revenue, by type, 2017 - 2024 (USD Billion)
      • 9.3.3. Europe ophthalmic drugs market revenue, by disease indication, 2017 - 2024 (USD Billion)
      • 9.3.4. Europe ophthalmic drugs market revenue, by distribution channel, 2017 - 2024 (USD Billion)
      • 9.3.5. U.K.
        • 9.3.5.1. U.K. ophthalmic drugs market revenue, by drug class, 2017 - 2024 (USD Billion)
        • 9.3.5.2. U.K. ophthalmic drugs market revenue, by type, 2017 - 2024 (USD Billion)
        • 9.3.5.3. U.K. ophthalmic drugs market revenue, by disease indication, 2017 - 2024 (USD Billion)
        • 9.3.5.4. U.K. ophthalmic drugs market revenue, by distribution channel, 2017 - 2024 (USD Billion)
      • 9.3.6. Germany
        • 9.3.6.1. Germany ophthalmic drugs market revenue, by drug class, 2017 - 2024 (USD Billion)
        • 9.3.6.2. Germany ophthalmic drugs market revenue, by type, 2017 - 2024 (USD Billion)
        • 9.3.6.3. Germany ophthalmic drugs market revenue, by disease indication, 2017 - 2024 (USD Billion)
        • 9.3.6.4. Germany ophthalmic drugs market revenue, by distribution channel, 2017 - 2024 (USD Billion)
      • 9.3.7. France
        • 9.3.7.1. France ophthalmic drugs market revenue, by drug class, 2017 - 2024 (USD Billion)
        • 9.3.7.2. France ophthalmic drugs market revenue, by type, 2017 - 2024 (USD Billion)
        • 9.3.7.3. France ophthalmic drugs market revenue, by disease indication, 2017 - 2024 (USD Billion)
        • 9.3.7.4. France ophthalmic drugs market revenue, by distribution channel, 2017 - 2024 (USD Billion)
      • 9.3.8. Rest of Europe
        • 9.3.8.1. Rest of Europe ophthalmic drugs market revenue, by drug class, 2017 - 2024 (USD Billion)
        • 9.3.8.2. Rest of Europe ophthalmic drugs market revenue, by type, 2017 - 2024 (USD Billion)
        • 9.3.8.3. Rest of Europe ophthalmic drugs market revenue, by disease indication, 2017 - 2024 (USD Billion)
        • 9.3.8.4. Rest of Europe ophthalmic drugs market revenue, by distribution channel, 2017 - 2024 (USD Billion)
    • 9.4. Asia Pacific
      • 9.4.1. Asia Pacific ophthalmic drugs market revenue, by drug class, 2017 - 2024 (USD Billion)
      • 9.4.2. Asia Pacific ophthalmic drugs market revenue, by type, 2017 - 2024 (USD Billion)
      • 9.4.3. Asia Pacific ophthalmic drugs market revenue, by disease indication, 2017 - 2024 (USD Billion)
      • 9.4.4. Asia Pacific ophthalmic drugs market revenue, by distribution channel, 2017 - 2024 (USD Billion)
      • 9.4.5. China
        • 9.4.5.1. China ophthalmic drugs market revenue, by drug class, 2017 - 2024 (USD Billion)
        • 9.4.5.2. China ophthalmic drugs market revenue, by type, 2017 - 2024 (USD Billion)
        • 9.4.5.3. China ophthalmic drugs market revenue, by disease indication, 2017 - 2024 (USD Billion)
        • 9.4.5.4. China ophthalmic drugs market revenue, by distribution channel, 2017 - 2024 (USD Billion)
      • 9.4.6. Japan
        • 9.4.6.1. Japan ophthalmic drugs market revenue, by drug class, 2017 - 2024 (USD Billion)
        • 9.4.6.2. Japan ophthalmic drugs market revenue, by type, 2017 - 2024 (USD Billion)
        • 9.4.6.3. Japan ophthalmic drugs market revenue, by disease indication, 2017 - 2024 (USD Billion)
        • 9.4.6.4. Japan ophthalmic drugs market revenue, by distribution channel, 2017 - 2024 (USD Billion)
      • 9.4.7. India
        • 9.4.7.1. India ophthalmic drugs market revenue, by drug class, 2017 - 2024 (USD Billion)
        • 9.4.7.2. India ophthalmic drugs market revenue, by type, 2017 - 2024 (USD Billion)
        • 9.4.7.3. India ophthalmic drugs market revenue, by disease indication, 2017 - 2024 (USD Billion)
        • 9.4.7.4. India ophthalmic drugs market revenue, by distribution channel, 2017 - 2024 (USD Billion)
      • 9.4.8. Rest of Asia Pacific
        • 9.4.8.1. Rest of Asia Pacific ophthalmic drugs market revenue, by drug class, 2017 - 2024 (USD Billion)
        • 9.4.8.2. Rest of Asia Pacific ophthalmic drugs market revenue, by type, 2017 - 2024 (USD Billion)
        • 9.4.8.3. Rest of Asia Pacific ophthalmic drugs market revenue, by disease indication, 2017 - 2024 (USD Billion)
        • 9.4.8.4. Rest of Asia Pacific ophthalmic drugs market revenue, by distribution channel, 2017 - 2024 (USD Billion)
    • 9.5. Latin America
      • 9.5.1. Latin America ophthalmic drugs market revenue, by drug class, 2017 - 2024 (USD Billion)
      • 9.5.2. Latin America ophthalmic drugs market revenue, by type, 2017 - 2024 (USD Billion)
      • 9.5.3. Latin America ophthalmic drugs market revenue, by disease indication, 2017 - 2024 (USD Billion)
      • 9.5.4. Latin America ophthalmic drugs market revenue, by distribution channel, 2017 - 2024 (USD Billion)
      • 9.5.5. Brazil
        • 9.5.5.1. Brazil ophthalmic drugs market revenue, by drug class, 2017 - 2024 (USD Billion)
        • 9.5.5.2. Brazil ophthalmic drugs market revenue, by type, 2017 - 2024 (USD Billion)
        • 9.5.5.3. Brazil ophthalmic drugs market revenue, by disease indication, 2017 - 2024 (USD Billion)
        • 9.5.5.4. Brazil ophthalmic drugs market revenue, by distribution channel, 2017 - 2024 (USD Billion)
      • 9.5.6. Rest of Latin America
        • 9.5.6.1. Rest of Latin America ophthalmic drugs market revenue, by drug class, 2017 - 2024 (USD Billion)
        • 9.5.6.2. Rest of Latin America ophthalmic drugs market revenue, by type, 2017 - 2024 (USD Billion)
        • 9.5.6.3. Rest of Latin America ophthalmic drugs market revenue, by disease indication, 2017 - 2024 (USD Billion)
        • 9.5.6.4. Rest of Latin America ophthalmic drugs market revenue, by distribution channel, 2017 - 2024 (USD Billion)
    • 9.6. The Middle East and Africa
      • 9.6.1. The Middle East and Africa ophthalmic drugs market revenue, by drug class, 2017 - 2024 (USD Billion)
      • 9.6.2. The Middle East and Africa ophthalmic drugs market revenue, by type, 2017 - 2024 (USD Billion)
      • 9.6.3. The Middle East and Africa ophthalmic drugs market revenue, by disease indication, 2017 - 2024 (USD Billion)
      • 9.6.4. The Middle East and Africa ophthalmic drugs market revenue, by distribution channel, 2017 - 2024 (USD Billion)
  •  
  • Chapter 10. Company Profile
    • 10.1. Allergan Plc
      • 10.1.1. Overview
      • 10.1.2. Financials
      • 10.1.3. Product portfolio
      • 10.1.4. Business strategy
      • 10.1.5. Recent developments
    • 10.2. Regeneron Pharmaceuticals, Inc.
      • 10.2.1. Overview
      • 10.2.2. Financials
      • 10.2.3. Product portfolio
      • 10.2.4. Business strategy
      • 10.2.5. Recent developments
    • 10.3. Pfizer, Inc.
      • 10.3.1. Overview
      • 10.3.2. Financials
      • 10.3.3. Product portfolio
      • 10.3.4. Business strategy
      • 10.3.5. Recent developments
    • 10.4. F.Hoffmann-La Roche Ltd.
      • 10.4.1. Overview
      • 10.4.2. Financials
      • 10.4.3. Product portfolio
      • 10.4.4. Business strategy
      • 10.4.5. Recent developments
    • 10.5. Santen Pharmaceutical Co., Ltd.
      • 10.5.1. Overview
      • 10.5.2. Financials
      • 10.5.3. Product portfolio
      • 10.5.4. Business strategy
      • 10.5.5. Recent developments
    • 10.6. Bayer AG
      • 10.6.1. Overview
      • 10.6.2. Financials
      • 10.6.3. Product portfolio
      • 10.6.4. Business strategy
      • 10.6.5. Recent developments
    • 10.7. Novartis AG
      • 10.7.1. Overview
      • 10.7.2. Financials
      • 10.7.3. Product portfolio
      • 10.7.4. Business strategy
      • 10.7.5. Recent developments
    • 10.8. Kyowa Hakko Kirin Co., Ltd.
      • 10.8.1. Overview
      • 10.8.2. Financials
      • 10.8.3. Product portfolio
      • 10.8.4. Business strategy
      • 10.8.5. Recent developments
    • 10.9. Valent Pharmaceuticals International, Inc.
      • 10.9.1. Overview
      • 10.9.2. Financials
      • 10.9.3. Product portfolio
      • 10.9.4. Business strategy
      • 10.9.5. Recent developments
    • 10.10. Johnson and Johnson Vision Care, Inc.
      • 10.10.1. Overview
      • 10.10.2. Financials
      • 10.10.3. Product portfolio
      • 10.10.4. Business strategy
      • 10.10.5. Recent developments
    • 10.11. Shire Plc
      • 10.11.1. Overview
      • 10.11.2. Financials
      • 10.11.3. Product portfolio
      • 10.11.4. Business strategy
      • 10.11.5. Recent developments

Methodology

Free Analysis

Ophthalmology deals with the diagnosis, treatment, and prevention of diseases which are associated with the visual system. Most of the eye-related disorders occur over a long period of time and at initial phase are usually asymptomatic or cause a slight decrease in the vision. However, over time this becomes quite distinct. Ophthalmologic disorders cannot be cured completely; however, the treatment aims at managing the disease indication to reduce the severity or slow its progression. Ophthalmologists provide around 85% of their procedure-based services to the seniors. Cataract surgery is the most frequent surgical procedure which is performed in many countries. 

Factors driving the ophthalmic drugs market are the increasing focus of the market players in the emerging economies to tap the unmet medical needs, increasing number of co-development agreements among leading players to make novel biological drugs which have less treatment duration, high proportion of visually challenged population, and generic manufacturers trying to strengthen their distribution networks for cost-effective drugs in developing regions. Moreover, rising prevalence of intraocular eye disorders, age-related macular degeneration, glaucoma, diabetic retinopathy, etc., in the elderly population is also boosting the global ophthalmic drugs market growth. Several organizations globally are increasing allocations on investments in research and development to come up with more effective novel biological agents. However, some of the factors like longer approval timelines required for ophthalmic drugs and loss of patent protection for drugs can hinder the market growth for ophthalmic drugs.

Global Ophthalmic Drugs Market

The ophthalmic drugs market is segmented based on drug type, disease indication, type, and distribution channel. Based on drug class, the market is segmented into anti-inflammatory drugs, antiglaucoma drugs, anti-allergic drugs, anti-infective drugs, and others. The anti-inflammatory drugs are further segmented into nonsteroidal anti-inflammatory drugs and steroids. The anti-infective drugs are further divided into anti-fungal drugs, anti-viral drugs, antibacterial drugs, and others. The anti-glaucoma drugs are segmented into combined medication, alpha agonist, prostaglandin analogs, beta blockers, and others. Based on type, the market is segmented into hospital prescription drugs and over-the-counter drugs. The ophthalmic drugs market is divided on the basis of disease indication into dry eye, allergies, glaucoma, retinal disorders, inflammation/infection, uveitis, and others. Based on the distribution channel, the market is segmented into online sales, retail pharmacies, hospital pharmacies, and others.

North America holds the largest share in the ophthalmic drugs market. This growth is mainly attributed to the huge number of R&D activities in the field of drug discovery. The region also has a large presence of a number of multinational biotech and pharma companies which carry out a large number of clinical trials and also have well developed and advanced healthcare infrastructure. Due to the high healthcare investment and rising government funding, Europe also holds a maximum share of the market followed by North America. Numerous market players are actively involved in the expansion of existing ophthalmic drugs to meet the rising demands for treatment of eye diseases. Besides, approval of new drugs for treating eye disorders by the European Union is also propelling the market for ophthalmic drugs in Europe. Asia Pacific region is also witnessing significant growth rate owing to the unmet health care needs and government funding towards research activities. Numerous ophthalmology companies are investing in the relatively untapped markets in the region to grow their revenue. India, China, and Malaysia are the most attractive markets in Asia Pacific owing to its rising healthcare spendings, substantial consumer base, and patient inclination to avail improved healthcare facilities.

Some of the leading players in ophthalmic drugs market include Allergan Plc, Regeneron Pharmaceuticals, Inc., Pfizer, Inc., Novartis AG, Bayer AG, F.Hoffmann-La Roche Ltd., Santen Pharmaceutical Co. Ltd., Kyowa Hakka Kirin Co. Ltd., Valent Pharmaceuticals International, Inc., Johnson and Johnson Vision Care, Inc., and Shire Plc. In March 2017, Allergan selected Aptar Pharma’s ophthalmic squeeze dispenser system for its new dry eye product, Restasis Multidose to treat the patients with the chronic dry eye. 

Office Address

Corporate Office
Zion Market Research 244 Fifth Avenue, Suite N202 New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll Free No.1-855-465-4651

Asia Pacific Office
3rd Floor, Mrunal Paradise, Opp Maharaja Hotel, Pimple Gurav, Pune 411061, Maharashtra, India
Phone No 020-46277770

Contact #
US OFFICE NO +1-386-310-3803
US/CAN TOLL FREE +1-855-465-4651
Email: sales@zionmarketresearch.com

We Accept

We have secured system to process your transaction.


We Are On Social